Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

Table 3 The steady-state plasma concentration of tamoxifen and its metabolites

[ng/ml]	Mean	SD	Median	Min	Max	Not detected^a
[ng/ml]	Mean	SD	Median	Min	Max	N = 279 (%)
Tamoxifen	173.53	67.68	169.76	41.4	402.10	0 (0)
NDM-Tam	235.53	97.04	220.53	33.20	810.16	0 (0)
(Z)-Endoxifen + 3-OH-NDM-Tam	5.55	3.26	4.90	0.55	18.23	0 (0)
(Z)-4-OH-Tam + 3-OH-Tam	2.46	1.20	2.45	0.12	5.66	0 (0)
(E)-Endoxifen	0.02	0.07	0	0.03	0.37	249 (89.2)
4′-OH-Tam	3.13	1.32	2.93	0.37	8.72	0 (0)
4′-OH-NDM-Tam	3.84	1.93	3.56	0.19	15.66	1 (0.4)
Tam-N-oxide	13.47	7.43	11.62	1.41	58.03	0 (0)
(E)-4-OH-Tam-O-gluc	0.23	0.17	0.18	0.03	1.19	1 (0.4)
(E/Z)-4-OH-NDM-Tam-gluc	1.12	1.02	0.88	0.10	11.49	0 (0)
(E/Z)-Tam-N-gluc	0.32	0.32	0.24	0.03	2.45	1 (0.4)
(E)-α-OH-Tam	0.36	0.17	0.37	0.02	1.02	8 (2.9)
(Z)-α-OH-Tam	0.04	0.03	0.04	0.02	0.19	116 (41.6)

^aThe number and (%) of patients with no detectable plasma concentration of compounds

ISSN: 1471-2407